))
NSAIDs, Part 3: The rise, fall and rise again of COX-2 inhibition
Manage episode 436874438 series 3560282
İçerik Healio, Adam J. Brown, and MD tarafından sağlanmıştır. Bölümler, grafikler ve podcast açıklamaları dahil tüm podcast içeriği doğrudan Healio, Adam J. Brown, and MD veya podcast platform ortağı tarafından yüklenir ve sağlanır. Birinin telif hakkıyla korunan çalışmanızı izniniz olmadan kullandığını düşünüyorsanız burada https://tr.player.fm/legal özetlenen süreci takip edebilirsiniz.
In the third episode of the NSAIDs saga, we focus on COX-2 inhibition! Did the hopes and dreams of selective COX-2 inhibition pan out? What can the rise and fall of VIOXX teach us about physiology?
- Intro 0:11
- Recap of part 1 & 2 0:28
- In this episode 1:44
- Cyclooxygenase 2 (COX-2) and the rat experiment 3:12
- What do we know about the prostaglandins? And what about COX-2 7:54
- What does prostacyclin do? 10:33
- The first COX-2 inhibitor: VIOXX 10:56
- What is COX-2 doing?: Pfizer and Merck 12:15
- Two more NSAID studies: colon cancer, Alzheimer’s disease and COX-2 inhibitors 18:41
- VIOXX: Why is myocardial infarction risk occurring? 22:34
- Animal models and the Goldilocks theory of thromboxane and prostacyclin 23:49
- PRECISION trial 30:25
- Rheum + Boards 37:14
- Thanks for listening 37:32
We’d love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum.
References:
Anderson GD, et al. J Clin Invest. 1996;doi:10.1172/JCI118717.
Funk CD, et al. J Cardiovasc Pharmacol. 2007;doi:10.1097/FJC.0b013e318157f72d.
Hennan JK, et al. Circulation. 2001;doi:10.1161/hc3301.092790.
Krumholz HM, et al. BMJ. 2007;doi:10.1136/bmj.39024.487720.68.
Nissen SE, et al. N Engl J Med. 2016;doi:10.1056/NEJMoa1611593.
Disclosures: Brown reports no relevant financial disclosures.
84 bölüm
Paylaş
